{
    "ticker": "CHRS",
    "name": "CohBar, Inc.",
    "description": "CohBar, Inc. is a biotechnology company focused on developing innovative therapeutics for age-related diseases and metabolic disorders. Founded in 2014, CohBar's research is centered on the discovery of mitochondrial-derived peptides (MDPs), which have been shown to play crucial roles in cellular function and metabolism. The company's proprietary platform leverages the unique properties of these peptides to create novel therapies that target a range of conditions, including obesity, diabetes, and neurodegenerative diseases. With a strong emphasis on scientific research, CohBar collaborates with leading academic institutions and industry partners to advance its pipeline of drug candidates. The company is driven by the mission to extend healthy lifespan and improve the quality of life for patients suffering from age-related diseases. CohBar aims to become a leader in the field of peptide-based therapeutics, capitalizing on the growing understanding of the role of mitochondria in health and disease. As the world faces an aging population, CohBar's innovative approach positions it well within the booming biotechnology sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Menlo Park, California, USA",
    "founded": "2014",
    "website": "https://www.cohbar.com",
    "ceo": "Joseph M. M. J. D. R. C. D. D. S. C. K. G. C. C. E. L. R. F. K. S.",
    "social_media": {
        "twitter": "https://twitter.com/CohBar",
        "linkedin": "https://www.linkedin.com/company/cohbar/"
    },
    "investor_relations": "https://www.cohbar.com/investors/",
    "key_executives": [
        {
            "name": "Joseph M. M. J. D. R. C. D. D. S. C. K. G. C. C. E. L. R. F. K. S.",
            "position": "CEO"
        },
        {
            "name": "Nicolas A. C. A. A. M. C.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CB4211",
                "CB5138-3"
            ]
        }
    ],
    "seo": {
        "meta_title": "CohBar, Inc. | Innovative Biotherapeutics for Age-Related Diseases",
        "meta_description": "CohBar, Inc. is at the forefront of biotechnology, developing novel therapies targeting age-related diseases through mitochondrial-derived peptides. Learn more about our innovative approach.",
        "keywords": [
            "CohBar",
            "Biotechnology",
            "Age-Related Diseases",
            "Peptide Therapeutics",
            "Mitochondrial Peptides"
        ]
    },
    "faq": [
        {
            "question": "What does CohBar specialize in?",
            "answer": "CohBar specializes in developing innovative therapeutics for age-related diseases and metabolic disorders using mitochondrial-derived peptides."
        },
        {
            "question": "Who is the CEO of CohBar?",
            "answer": "The CEO of CohBar is Joseph M. M. J. D. R. C. D. D. S. C. K. G. C. C. E. L. R. F. K. S."
        },
        {
            "question": "Where is CohBar headquartered?",
            "answer": "CohBar is headquartered in Menlo Park, California, USA."
        },
        {
            "question": "What are some of CohBar's main products?",
            "answer": "Some of CohBar's main products include CB4211 and CB5138-3."
        },
        {
            "question": "When was CohBar founded?",
            "answer": "CohBar was founded in 2014."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "BIIB",
        "MRNA",
        "ALNY"
    ]
}